• M F Solano L, F Alvarez Lerma, S Grau, C Segura, and A Aguilar.
• Servicio de Enfermedades Infecciosas, Hospital del Mar, Universidad Autónoma de Barcelona, Barcelona, España. Electronic address: mafe115@gmail.com.
• Med Intensiva. 2015 Jan 1; 39 (1): 13-9.

ObjectiveTo describe the epidemiological characteristics of the population with Pneumocystis jiroveci (P. jiroveci) pneumonia, analyzing risk factors associated with the disease, predisposing factors for admission to an intensive care unit (ICU), and prognostic factors of mortality.Design And PatientsA retrospective observational study was carried out, involving a cohort of patients consecutively admitted to a hospital in Spain from 1 January 2007 to 31 December 2011, with a final diagnosis of P. jiroveci pneumonia.SettingThe ICU and hospitalization service of Hospital del Mar, Barcelona (Spain).ResultsWe included 36 patients with pneumonia due to P. jiroveci. Of these subjects, 16 required ICU admission (44.4%). The average age of the patients was 41.3 ± 12 years, and 23 were men (63.9%). A total of 86.1% had a history of human immunodeficiency virus (HIV) infection, and the remaining 13.9% presented immune-based disease subjected to immunosuppressive therapy. Risk factors associated to hospital mortality were age (51.8 vs. 37.3 years, P=.002), a higher APACHE score upon admission (17 vs. 13 points, P=.009), the need for invasive mechanical ventilation (27.8% vs. 11.1%, P=.000), requirement of vasoactive drugs (25.0% vs. 11.1%, P=.000), fungal coinfection (22.2% vs. 11.1%, P=.001), pneumothorax (16.7% vs. 83.3%, P=.000) and admission to the ICU (27.8% vs. 72.2% P=.000).ConclusionsThe high requirement of mechanical ventilation and vasoactive drugs associated with fungal coinfection and pneumothorax in patients admitted to the ICU remain as risk factors associated with mortality in patients with P. jiroveci pneumonia.Copyright © 2013 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

32 keywords...

hide…